Technical Analysis for CARA - Cara Therapeutics, Inc.

Grade Last Price % Change Price Change
grade B 20.1 1.88% 0.37
CARA closed up 1.88 percent on Wednesday, June 26, 2019, on 69 percent of normal volume.
14 Watchers
View Intraday Alerts Watchlist Portfolio

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Up Up Up
See historical CARA trend table...

Date Alert Name Type % Chg
Crossed Above 20 DMA Bullish 0.00%
Bollinger Band Squeeze Range Contraction 0.00%
Multiple of Ten Bullish Other 0.00%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 1.88%
Bollinger Band Squeeze Range Contraction 1.88%
NR7 Range Contraction 1.88%
BB Squeeze Started Range Contraction 1.88%
Fell Below 20 DMA Bearish 2.71%
MACD Bearish Signal Line Cross Bearish 2.71%
Multiple of Ten Bearish Other 2.71%

Older signals for CARA ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Get Started for Free!
Configure default chart indicators
Basic chart:
Profile
Cara Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics to treat pain. Its products include intravenous CR845 that has completed Phase II clinical trials for the treatment of acute postoperative pain in adult patients; Oral CR845, which is in Phase I clinical trials to treat acute and chronic pain; and CR701 that is in preclinical trials for treating neuropathic and inflammatory pain. The company was founded in 2004 and is based in Shelton, Connecticut.
Chemistry Health Biopharmaceutical Pain Clinical Trial Piperidines Amines Mesoblast
Is CARA a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 3 bullish, 0 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Recent News
Date Title
Jun 26 Cara Therapeutics Announces Initiation of Phase 2 Trial of Oral KORSUVAᵀᴹ (CR845/difelikefalin) for Pruritus in Patients with Primary Biliary Cholangitis (PBC)
Jun 11 Cara's Second Half Catalyst Has The Potential To Change The Scope Of The Biotech Forever
Jun 10 Cara Therapeutics: Positive Phase III KALM-1 Results Make Me Feel Calm
Jun 7 Cara Therapeutics (CARA) Presents At Jefferies 2019 Healthcare Conference - Slideshow
Jun 2 Is Cara Therapeutics a Buy Now?
May 31 Cara Therapeutics to Present at the Jefferies 2019 Healthcare Conference
May 30 Cara Shares Up on Positive Phase III Data for Itchiness Drug
May 29 Cara Therapeutics Surges on Phase 3 Results for Itchiness Treatment
May 29 Stocks making the biggest moves midday: Canada Goose, Capri Holdings, General Mills & more
May 29 AMRN, CARA, ANF and GOOS among midday movers
See more CARA news...
Indicators
Indicator Value
52 Week High 24.3
52 Week Low 12.19
Average Volume 777,390
200-Day Moving Average 18.3313
50-Day Moving Average 19.4008
20-Day Moving Average 20.0985
10-Day Moving Average 19.904
Average True Range 0.8369
ADX 12.05
+DI 24.4649
-DI 16.5605
Chandelier Exit (Long, 3 ATRs ) 19.4193
Chandelier Exit (Short, 3 ATRs ) 20.3107
Upper Bollinger Band 21.0006
Lower Bollinger Band 19.1964
Percent B (%b) 0.5
BandWidth 8.976789
MACD Line 0.1475
MACD Signal Line 0.1845
MACD Histogram -0.0371
Fundamentals Value
Market Cap 654.87 Million
Num Shares 32.6 Million
EPS -2.28
Price-to-Earnings (P/E) Ratio -8.82
Price-to-Sales 424.16
Price-to-Book 3.54
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 21.08
Resistance 3 (R3) 21.10 20.80 20.91
Resistance 2 (R2) 20.80 20.55 20.79 20.86
Resistance 1 (R1) 20.45 20.40 20.63 20.43 20.80
Pivot Point 20.15 20.15 20.24 20.14 20.15
Support 1 (S1) 19.80 19.90 19.98 19.78 19.40
Support 2 (S2) 19.50 19.75 19.49 19.34
Support 3 (S3) 19.15 19.50 19.29
Support 4 (S4) 19.13